TYK2-IN-2

Target: This ligand targets tyrosine kinase 2 (TYK2), reported for the regulatory JH2 pseudokinase domain in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for tyrosine kinase 2 (TYK2), reported for the regulatory JH2 pseudokinase domain. In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings tyrosine kinase 2 (TYK2) into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• TYK2 DEGRADATION PROTAC DEVELOPMENT: TYK2-IN-2 can serve as a high-affinity ligand module for building PROTACs aimed at inducing selective TYK2 degradation. By coupling this ligand to an E3 ligase recruiter, researchers can evaluate ternary complex formation, ubiquitination efficiency, and degradation potency to map structure–activity relationships and optimize degradation kinetics.

• E3 LIGASE RECRUITER OPTIMIZATION: Incorporating TYK2-IN-2 into PROTAC architectures with different E3 ligase ligands enables systematic screening of recruiter compatibility. This approach supports identification of the most productive ubiquitin–proteasome pathway engagement, improving degradation depth and duration while probing how ligase selection influences TYK2 turnover in relevant cellular contexts.

• PATHWAY-BASED FUNCTIONAL STUDIES: PROTACs using TYK2-IN-2 as the targeting element can be applied to dissect TYK2-dependent signaling outputs, including downstream phosphorylation events and cytokine-stimulated transcriptional responses. Comparing degradation versus inhibition phenotypes helps clarify whether complete TYK2 removal yields distinct pathway rewiring, offering mechanistic insight into TYK2 biology.

• SELECTIVITY AND OFF-TARGET PROFILING: TYK2-IN-2–based PROTACs can be used to assess target selectivity by monitoring degradation across related kinases and signaling proteins. Proteomic or immunoblot-based profiling can quantify on-target degradation specificity, detect potential off-target ubiquitination, and guide iterative ligand or linker modifications to enhance degradation selectivity.

• KINETICS AND RESISTANCE MECHANISM MAPPING: Using TYK2-IN-2 in PROTAC experiments allows evaluation of degradation kinetics, including onset time, maximal depletion, and recovery after washout. These studies can reveal how cellular adaptation or pathway compensation affects TYK2 turnover, supporting rational design of next-generation constructs to mitigate resistance to targeted degradation.

Structure: The structure of TYK2-IN-2 is characterized by primary or secondary amine/basic nitrogen centers; amide/urea/sulfonamide hydrogen-bonding motifs; heteroaromatic protein-recognition scaffold. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The amine/basic nitrogen-containing motif can be evaluated for acylation, sulfonylation, alkylation, or carbamate/urea linker installation when that vector is solvent exposed. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.